Cassava Sciences Inc logo

SAVA

Cassava Sciences Inc

$26.5

Earnings Summary

Revenue
$0Mn
Net Profits
$-17.53Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Cassava Sciences Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Cassava Sciences Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Cassava Sciences Inc’s net profit fell -397.08% since last year same period to $-17.53Mn in the Q1 2022. On a quarterly growth basis, Cassava Sciences Inc has generated -23.67% fall in its net profits since last 3-months.

Net Profit Margins:

Cassava Sciences Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Cassava Sciences Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Cassava Sciences Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.43
EPS Estimate Current Year
-0.43

Highlights

EPS Estimate Current Quarter:

Cassava Sciences Inc’s earning per share (EPS) estimates for the current quarter stand at -0.43 - a -4.88% fall from last quarter’s estimates.

EPS Estimate Current Year:

Cassava Sciences Inc’s earning per share (EPS) estimates for the current year stand at -0.43.

Key Ratios

Key ratios of the Cassava Sciences Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-0.48

Highlights

Earning Per Share (EPS):

Cassava Sciences Inc’s earning per share (EPS) fell -269.23% since last year same period to -0.48 in the Q2 2022. This indicates that the Cassava Sciences Inc has generated -269.23% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.41
-0.44
-7.32%
2022-08-03
-0.43
-0.48
-11.63%

Company Information

Cassava Sciences' mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer's disease.

Organisation
Cassava Sciences Inc
Headquarters
Austin, Texas, US
Employees
11
Industry
Pharmaceuticals: Other
CEO
Remi Barbier